GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to ...

GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a ...

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

Barclays lowered the firm’s price target on GSK (GSK) to 1,450 GBp from 1,550 GBp and keeps an Equal Weight rating on the shares.

BRENTFORD, Britain (AP) — BRENTFORD, Britain (AP) — GSK plc (GSK) on Wednesday reported a loss of $75.4 million in its third quarter. The Brentford, Britain-based company said it had a loss of ...

Welcome to today's call and webcast. The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to Slide 2. This is the usual safe harbor ...

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in Specialty ...